MedTrace Logo

Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis

NCT01305837 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-07-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether cyclic oral methylprednisolone once every month has an effect on the intrathecal inflammation in patients suffering from progressive multiple sclerosis.

Conditions

Interventions

DRUG

methylprednisolone

500 mg of methylprednisolone taken in 3 days every month

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Rikke Ratzer, MD · Scleroseklinikken, Rigshospitalet

  • Per S Sørensen, Professor, MD · Scleroseklinikken, Rigshospitalet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01305837 on ClinicalTrials.gov